Septerna, Inc. (NASDAQ:SEPN - Get Free Report)'s share price gapped down prior to trading on Monday . The stock had previously closed at $23.69, but opened at $22.88. Septerna shares last traded at $23.43, with a volume of 2,627 shares trading hands.
Analyst Ratings Changes
SEPN has been the topic of several research reports. Cantor Fitzgerald assumed coverage on Septerna in a report on Tuesday, November 19th. They set an "overweight" rating and a $50.00 price objective on the stock. Wells Fargo & Company assumed coverage on Septerna in a report on Tuesday, November 19th. They issued an "overweight" rating and a $43.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an "overweight" rating and a $38.00 target price on the stock. Finally, TD Cowen assumed coverage on shares of Septerna in a research report on Tuesday, November 19th. They set a "buy" rating on the stock.
Check Out Our Latest Stock Report on Septerna
Septerna Trading Down 6.8 %
The stock's 50 day simple moving average is $23.70.
Insider Transactions at Septerna
In related news, major shareholder Rock Ventures V. L.P. Third acquired 370,500 shares of the firm's stock in a transaction that occurred on Monday, October 28th. The shares were purchased at an average price of $18.00 per share, with a total value of $6,669,000.00. Following the completion of the acquisition, the insider now owns 6,215,591 shares in the company, valued at approximately $111,880,638. This represents a 6.34 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.
About Septerna
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Further Reading
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
